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Abstract
Prediction of microscopic spread of tumor cells is be-
coming critically important in the decision making
process in planning radiation therapy for cancer. Un-
til recently, radiation treatment of head and neck can-
cer has been conservative, treating large regions to in-
sure eradication of disease. However, if it is known
that regional spread is conﬁned, a more focused treat-
ment can be considered, with the payoff of reducing or
eliminating morbidity due to irradiating healthy tis-
sue in the vicinity of node groups. Knowledge about
the occurrence of micrometastases comes mainly from
pathology reports in connection with surgery. As the
data accrue, it will be possible and necessary to rep-
resent this knowledge in a symbolic computational
model. Our work reports on the feasibility of modeling
this knowledge using published data.
INTRODUCTION
Radiation oncology has played a prominent role in
the management of head and neck cancers. Radiation
oncologists have used surgically-derived data to de-
sign traditional radiotherapy ﬁelds that treat the obvi-
ous primary tumor and electively treat adjacent lymph
node levels felt to be at signiﬁcant risk for subclinical
disease. Given the limitations of traditional technol-
ogy and radiation delivery systems, these ﬁelds have
historically been comprehensivein nature since highly
selective targetingof individual lymph node levels and
exclusion of others was impossible in many clinical
situations. This technological limitation is being over-
come, and therefore radiation oncologists are begin-
ning to reevaluate the available literature in order to
rationally design highly selective treatment ﬁelds.
One such technique, intensity-modulated radiation
therapy (IMRT),
￿
shows great promise. This tech-
nique achieves a high dose to a deﬁned target region
with a sharp falloff at the boundary. Figure 1 shows
a cross sectional view of a treatment plan using IMRT
for a clival meningioma. The tumor is in a region be-
tween the optic chiasm and the brain stem, and has an
elongated shape unsuitable for conventionalradiother-
apy. Achieving a sharp falloff at the boundary results
in lower dose to the surrounding critical organs, with
consequent reduced morbidity, or alternately allows a
higher dose to the tumor, giving better local control
(destruction of all the tumor cells).
This of course assumes that the radiation oncologist
is able to precisely delineate (for each patient individ-
ually) the target volume, i.e., the volume to irradiate.
￿
In fact, there is no computational technique at present
for doing this. The radiation oncologist draws outlines
representinghis/her best estimate of how far the tumor
has spreadmicroscopicallyfromthe primarysite. This
depends on the size of the tumor, the type of cells, and
most critically the surrounding anatomy. Tumor cells
migrate along lymph drainages, and along nerves in
some cases. They cannot be made visible with any
imaging techniques known today.
Pathology ﬁndings following surgery have been re-
ported in the literature, usually to address speciﬁc
questions such as whether or not to include a spe-
ciﬁc node group in the target volume. Generally tumor
spread largely follows anatomic structure and biologic
principles, but no computational models for this have
been proposed. As tumors become larger and time
elapses, the probability of more distant node groups
being positive for microscopic spread increases.
The goal of our work is to propose and validate
a computational model of local and regional disease
spread based on production rules, representing clini-
cal data, anatomic knowledge and clinical judgement.
The work reported here is the ﬁrst step in this direc-
tion. A truly powerfulsystem implementingthe model
would also need to be able to apply image processing
techniques to compute the boundaries of the selected
nodal regions in a patient speciﬁc way. Work is also
in progress to solve this problem and will be reported
elsewhere.
Themodelwedescribeis beingdevelopedas acom-
ponent of the Prism radiation therapy planning sys-
tem,
￿
developed and in clinical use at the UniversityFigure 1: A cross-sectional view of an IMRT radiation treatment plan. The nine treatment ﬁelds are each modulated
across their apertures to produce the very tailored dose distribution shown, which avoids the brain stem, the optic
chiasm and as much as possible of the rest of the surrounding brain tissue.
of Washington Cancer Center. This will give us the
opportunity in the future to test the model in a clinical
environment, and demonstrate how it can be deployed
clinically, so that it can have a real impact on practice.
TUMOR SITES AND NODAL REGIONS
Head and neck cancers are a heterogeneous collection
of malignancies arising in multiple anatomic subsites,
each with uniqueclinical, pathological,andprognostic
features. The vast majority of these cancers are squa-
mous cell carcinomas that originate in the normal mu-
cosal lining located throughout the head and neck. As
these squamous cancers enlarge, they tend to spread
from primary location to nearby regional lymph nodes
in a predictable sequence. Curative treatment of these
cancers, therefore, has historically required attention
to the draining regional lymph nodes that could harbor
microscopic disease.
The development of standardized surgical ap-
proaches to the neck (e.g., radical neck dissection, se-
lective neck dissection) has paralleled development of
standardized nomenclature for the various nodal re-







In addition, several published series of surgically-
Table 1: Currentclassiﬁcation of cervicallymphnodes
Level Ia Submental group
Level Ib Submandibular group
Level II Upper jugular group
Level III Middle jugular group
Level IV Lower jugular group
Level V Posterior triangle group
treatedpatientshaveprovidedvaluablepathologicdata
allowing statistical estimation of the risk for subclini-














The example data shown in Table 2 are
adapted from Shah, et. al.
￿
RULES FROM PUBLISHED DATA
We initially intended to generate production rules
based solely upon published statistics of metastatic tu-
mor spread in the head and neck. The literature con-
tains a number of studies examining the probability of
neck metastases for various primary sites. The ma-
jority of these studies publish overall probabilities ofTable 2: Prevalence of subclinical lymph node involvement according to tumor site
Tumor location
Nodal Level Oral tongue Floor of mouth Alveolar ridge Retromolar trigone Buccal mucosa
I 14% 16% 27% 19% 44%
II 19% 12% 21% 12% 11%
III 16% 7% 6% 6% 0%
IV 3% 2% 4% 6% 0%
V 0% 0% 2% 0% 0%
metastasis broken down by the T stage of primary tu-
mor. Unfortunately, few studies report the levels of










sons account for the lack of speciﬁc data on the loca-
tion of neck metastases. Typically, these studies use
the pathologic specimens from a series of neck dissec-
tions. These pathologic specimens do not necessarily
contain the landmarks that allow the surgical patholo-
gist todeterminethe anatomiclocationoflymphnodes
within the specimen. Additionally, in the past several
decades, selective neck dissections that do not remove
all of the lymphatic contents of the neck have become
thestandardofcarefora varietyoflowerstage tumors.
In these cases, the presence of micro-metastases in the
undissected areas can only be inferred from the inci-
dence of treatment failures in these areas.
Unfortunately for our purposes, most of the stud-
ies that break down metastases by location in the neck
do not report these results by the T and N stage of
the primary tumor. To create production rules that
specify which levels of the neck to treat for a speciﬁc
TNM stage primary tumor, we need probabilities for
the presence of tumor in each level of the neck for
each TNM stage. Although this information was not
reported in these studies, we inferred conservative es-
timates of these probabilities from the published data.
This was accomplished by utilizing the reported over-
all percentage of patients at each T and N stage and
the reported overall probabilities of tumor metastasis
at each neck level (independent of T stage). To cal-
culate an upper limit of probability, we made use of
the evidencethat a moreadvancedstage squamouscell
carcinoma (higher T and N stage) is more likely to
exhibit regional metastases than a lower stage SCCA
of the same primary site. For each primary site and
each level of the neck, the number of positive metas-
tases was reported. For each T and N stage, we calcu-
lated the probability of metastasis for each neck level
by dividing the number of positive metastases at that
level by the sum of the patients with the given T and N
stage and all patients with a higherT and N stage. This
method likely overestimates the probability of metas-
tasis at a given T and N stage. This is due to fact
that calculating the metastatic probability in the man-
ner assumes that all metastases occur within the pa-
tients with at least the given T and N stage, and that
the distribution of the metastases within this group of
patientsis uniform. In realitythedistributionof metas-
tases isprobablyskewedtowardsmoreadvancedTand
N stages, but is unlikely to be skewed towards less ad-
vanced T and N stages. So by assuming a uniform
distribution, we can estimate the maximum probabil-
ity that a given T and N stage would metastasize to a
speciﬁc level of the neck.
Additional estimates can be formulated in a similar
manner, from studies that report an overall incidence
of metastasis by speciﬁc T and/or N stage. For each T
and N stage, the number of overall metastases can be
assigned to each level of the neck. Clearly, this also
is overestimating the probability of individual metas-
tases, but by combining the results of multiple studies
and choosing the lowest “upper margin” of probabil-
ity, a more accurate estimate can be achieved. How-
ever, additional factors complicate the effort to com-
bine the results of different studies. In addition to
factors mentioned previously, other factors include the
type of study (prospective vs. retrospective), the num-
ber of patients included, and the degree of speciﬁcity
used to classify the primary tumor site.
We collected data from several large prospective
and retrospectivestudies, limiting our focus initially to
squamous cell carcinomas of the oral cavity, orophar-
ynx, hypopharyx and larynx. Not surprisingly, there
tended to be a trade-off between speciﬁc primary tu-
mor sites and large sample size. We used the most
speciﬁc primary tumor site possible, given the avail-
able data in each study. When data were available on
the same primary site from different studies, we uti-
lized the results for the more speciﬁc primary site, as









￿ ) were reported.
When the sample size was small, we used data from
moregeneralprimarysites. Inpractice,nosinglestudy
contained sufﬁcient data to compute complete proba-
bilities for all primary sites. Rather a subjective com-pilation of the data was used to determine treatment
recommendations. A shortcoming of most of the stud-
ies was the lack of information on contralateral metas-
tases.
We ran our calculations with treatment thresholds
of 15%, 10% and 5%. That is, if the preponderance of
the data indicated a metastatic probability of 15% or
greater (or 10% or 5%), we would generate a rule to
treat that level of the neck.
ANATOMIC MODEL OF THE
LYMPHATIC DRAINAGE OF THE NECK
An advantage in treating squamous cell carcinoma of
the head and neck is the relatively constant and or-
derly progression of lymph node metastases in the un-
treated neck. The primary and secondary lymphatic
drainage of the various primary sites has been well
described. We sought to correlate the literature data
on nodal metastases with the anatomic model of lym-
phatic drainage, in order to support the literature data
when available, and augment areas where the liter-
ature is lacking. Using the Foundational Model of
Anatomy (FM) developed by the University of Wash-




all references to lymph nodes of the head and neck.
The majority of nodal groups described in the liter-
ature were included in the FM, with the notable ab-
sence of a speciﬁc reference to the deep middle cervi-
cal nodes that lie in level III of the neck. Moreover,
the FM lacks the anatomic relationship between pri-
mary sites of the head and neck and the nodal groups
with drain these sites. These relationships were con-
structed from the anatomic literature to be used in the
decision hierarchy.
SURVEY OF EXPERT PHYSICIANS
As noted above, the published literature allows us to
estimate an upper limit to the probability of regional
neck metastasis. This upper limit is probably more ac-
curate for more advanced disease, since the distribu-
tion of metastasis is likely skewed towards more ad-
vanced primary tumors. For less advanced disease this
method may greatly overestimate metastatic potential.
These less advanced tumors represent an area where
IMRT can provide improved outcomes, so determin-
ing a more accurate estimation of which neck levels
require treatment is an important goal. Radiation on-
cologists and head and neck surgeons make educated
guesses of these probabilities when treating patients
with head and neck cancer. We surveyed four radia-
tion oncologists in both an academic and private prac-
tice setting. In addition we surveyed three head and
neck surgeons, all of whom practice in an academic
setting. Each has signiﬁcant experience treating head
and neck cancer patients. These experts were asked
to identify which lymph node levels (ipsilateral Ia-V,
contralateral Ia-V) they would include in a clinical tar-
get volume for six hypothetical head and neck cancer
patients desiring treatment with deﬁnitive conformal
radiotherapy. The six selected cases used in the survey
are listed in Table 3 along with the number of experts
who recommended treatment of each lymph node re-
gion. All cases were presumed to be squamous cell
carcinomas.
None of the six hypothetical cases produced com-
plete agreement among the experts as to which cervi-
callymphnodelevelsshouldbeincludedintheclinical
target volume. The agreement was greater for certain
tumor sites and certain node groups. There was no
discernable difference between the two types of physi-
cians (radiation oncologists and surgeons).
RESULTS AND DISCUSSION
We usedtheresults oftheexpertsurveytotest theliter-
ature and our anatomic based model. We used the ﬁve
hypothetical cases relating to tumors of the oral cav-
ity,oropharynx,andhypopharynx,sincerulesforthese
systems had been developed. Scores were obtained
by calculating the percentage of expert opinions that
agreed with the system’s recommendation in either a
decision to treat or not to treat. Scores were calcu-
lated from rules generated using treatment thresholds
of 15%, 10%, and 5% chance of metastasis at a given
neck level. Using a threshold of 15% the agreement
between the system and the experts was 66.3%. An
agreement rate of 68% was obtained using a thresh-
old of 10%, and a rate of 74.3% was obtained using a
threshold of 5%. We also calculated the agreement be-
tween each expert and the others, in order to estimate
the degreeto which the experts agree on treatment rec-
ommendations. The agreement rate of an individual
expert, compared to the others, ranged from 79-81%,
with an overall agreement rate of 80%. Not surpris-
ingly, the 10% and 15% thresholds erred on the side
of under-treating disease for which the experts recom-
mendedtreatment,while the 5% thresholderredon the
side of over-treating disease for which the experts did
not recommend treatment. From these results it ap-
pears that the experts’ threshold for treatment lies in
the range of 5-10% probability of metastatic disease.
The results show that even with the limitations in-
herent in published data, it is feasible to create a rule-
based system for automatically determining which
nodal regions should be included in the treatment vol-
ume. However, to develop a really accurate system,
additional data will be required. Further, the type of
analysis and reporting of pathologic ﬁndings will need
tochange. ThemodelwearetryingtodeveloprequiresTable 3: Results of the expert survey
Number of experts including lymph node region
Description of ipsilateral contralateral
Hypothetical cases Ia Ib II III IV V Ia Ib II III IV V
T1N0M0 L tonsil 1 4 4
T2N0M0 R base of tongue 1 3 5 5 5 3 1 2 4 4 3 2
T3N0M0 L ﬂoor of mouth 4 5 5 5 5 3 4 5 5 2
T1N0M0 L nasopharynx 1 2 5 5 4 5 1 2 5 5 3 5
T2N0M0 R pyriform sinus 5 5 5 3 5 5 5 2
T2N0M0 L lateral oral tongue 3 5 5 5 5 2 4 4 4 2
a change in the kinds of questions to be asked. In-
stead of generalized“Should we treat level IV for base
of tongue tumors”, the data must be accumulated rou-
tinely with speciﬁcity of staging and specimen origin.
ThiskindofpathologicstudyisnowroutineattheUni-
versity of Washington Medical Center, and will allow
more reﬁnement in the system as it is built.
In this study, the hierarchical application of rules
was done by hand. In an actual system, a hierarchical
representationof the tumorprimarysites and a conﬂict
resolution strategy will have to be coded as part of the
design.
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